Fidaxomicin versus Vancomycin as a First‐Line Treatment for Clostridium difficile–Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation

Abstract

Fidaxomicin as first-line CDAD therapy is associated with similar total costs as compounded vancomycin oral solution in the general population. In elderly and renally impaired patients, slight increases in hospital cost were observed with fidaxomicin therapy, and in patients with cancer or concomitant antibiotic use, hospital cost savings were observed.

Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection — An observational cohort study

“…In this study, a higher recurrent CDI rate (29.2%) was identified in a large group of patients that represents an economic burden on the healthcare system. The group of patients treated with fidaxomicin had a significantly reduced rCDI rate compared to metronidazole and vancomycin groups (12% vs 35%, 38%), thus the introduction of fidaxomicin into therapy may have a long-term economic effect as was shown previously [31][32][33][34].…”

“…Despite the higher cost of fidaxomicin, its cost-effectiveness related to vancomycin or metronidazole as a first-line treatment for CDI, was proven in several analyses where its use resulted in fewer re-hospitalisations due to rCDI [31][32][33][34]. In this study, a higher recurrent CDI rate (29.2%) was identified in a large group of patients that represents an economic burden on the healthcare system.…”

Determinants of Environmental Sanitation Related to the Incidence of Diarrhea among Infants

“…Nutritional status, microbiology, and immunological factors have implications for the incidence of diarrhea in several countries. Food and beverage sanitation determinants influence the incidence of diarrhea in children under five, supported by poor environmental sanitation and personal hygiene [29].…”

Combating Resistance While Maintaining Innovation: The Future of Antimicrobial Stewardship

“…However, we see restrictions to the use of fidaxomicin, a drug shown to reduce rates of recurrent CDI when used frontline [51,52], to potentially reduce 28 day all-cause mortality [53], and is not associated with colonization or spread of VRE [54]. The often-cited 'justification' for this scenario is the high acquisition cost of fidaxomicin despite considerable evidence demonstrating wider health economic benefits [55][56][57][58].…”